Here are five takeaways:
1. Driving factors of the market are innovative technological advancements, advantages of biologics, demand for minimally invasive surgery and new treatment techniques and devices.
2. Potential restraints include unfavorable reimbursement policies, high costs, lack of professional experience and ethical issues associated to bone grafting procedures.
3. DePuy Spine, Medtronic, Stryker, Smith & Nephew, NuVasive and Zimmer Spine are key influencers of the market.
4. Surgeries analyzed by the market include anterior cervical discectomy and fusion, anterior lumbar interbody fusion, transforaminal lumbar interbody fusion and lateral lumber interbody fusion.
5. The biologics market covers bone graft substitutes, platelet rich plasma, bong grafts and bone marrow aspirate concentrate therapy.
More articles on spine:
AANS recognizes Dr. Victor Kareh with Continuing Education Award in Neurosurgery: 6 highlights
Spine surgeon joins Novant Health: 3 insights
CMS proposes 2 new spine codes for the ASC payable list
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
